Insulin degludec/Liraglutide(Dongyangguang)

德谷胰岛素利拉鲁肽（东阳光）

Report date: 2024/04/17 14:16:29

Base Information

Drug NameInsulin degludec/Liraglutide(Dongyangguang)
Drug Alias Name地谷胰岛素/利拉鲁肽地谷胰岛素/利拉糖肽
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsInsulin receptor agonists
TargetsGlucagon-like peptide 1 receptorInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDongguan City Hec Biological Medicine Res And Development Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDongguan City Hec Biological Medicine Res And Development Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A